Skip to main content
Videos

Roflumilast Cream for Atopic Dermatitis in Pediatric Dermatology


Arcutis announces Food and Drug Administration (FDA) acceptance of its supplemental new drug Application for ZORYVE (roflumilast) Cream 0.05% for treating mild-to-moderate atopic dermatitis in children ages 2-5. Dr Patrick Burnett discusses the significance of this non-steroidal treatment, its rapid itch relief within 24 hours, and its role in long-term disease management.

Patrick Burnett, MD, PhD, FAAD, serves as the chief medical officer of Arcutis Biotherapeutics.

© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of The Dermatologist or HMP Global, their employees, and affiliates.